Related references
Note: Only part of the references are listed.Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases
Eleonore Beurel et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Using ancient protein kinases to unravel a modern cancer drug's mechanism
C. Wilson et al.
SCIENCE (2015)
A study of the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands
David C. Swinney et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
Recent Developments in Drug Discovery for Leishmaniasis and Human African Trypanosomiasis
Advait S. Nagle et al.
CHEMICAL REVIEWS (2014)
A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy
Eduardo Tolosa et al.
MOVEMENT DISORDERS (2014)
Phenotypic vs. Target-Based Drug Discovery for First-in-Class Medicines
D. C. Swinney
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Dual-Point Competition Association Assay: A Fast and High-Throughput Kinetic Screening Method for Assessing Ligand-Receptor Binding Kinetics
Dong Guo et al.
JOURNAL OF BIOMOLECULAR SCREENING (2013)
Evidence for Irreversible Inhibition of Glycogen Synthase Kinase-3β by Tideglusib
Juan Manuel Dominguez et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
How were new medicines discovered?
David C. Swinney et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Drug-target residence time: critical information for lead optimization
Hao Lu et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2010)
Sartan-AT1 receptor interactions: In vitro evidence for insurmountable antagonism and inverse agonism
I. Van Liefde et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2009)
A novel GSK-3 beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo
L. Sereno et al.
NEUROBIOLOGY OF DISEASE (2009)
Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy
Kayode K. Ojo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Current concepts - Control of neglected tropical diseases
Peter J. Hotez et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin
Alfred A. Bartolucci et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Opinion - Drug-target residence time and its implications for lead optimization
Robert A. Copeland et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Slow antagonist dissociation and long-lasting in vivo receptor protection
Georges Vauquelin et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2006)
Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans
Georges Vauquelin et al.
JOURNAL OF HYPERTENSION (2006)
Biochemical mechanisms of drug action: what does it take for success?
DC Swinney
NATURE REVIEWS DRUG DISCOVERY (2004)
The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase:: Adduct affinity and drug resistance
R Rawat et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Share Paper
